Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

被引：60

作者：

Finney, Lydia ^{[1
,2
]}

Berry, Matthew ^{[1
,2
]}

Singanayagam, Aran ^{[1
,2
]}

Elkin, Sarah L. ^{[1
,2
]}

Johnston, Sebastian L. ^{[1
,2
]}

Mallia, Patrick ^{[1
,2
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Infect Sect, London W2 1PG, England

[2] Imperial Coll Healthcare NHS Trust, London, England

来源：

LANCET RESPIRATORY MEDICINE | 2014年 / 2卷 / 11期

关键词：

COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; FLUTICASONE PROPIONATE/SALMETEROL 250/50; SECONDARY BACTERIAL-INFECTION; HUMAN ALVEOLAR MACROPHAGES; LUNG EPITHELIAL-CELLS; METERED-DOSE INHALER; LONG-TERM USE; COPD PATIENTS; GLUCOCORTICOID-RECEPTOR;

D O I：

10.1016/S2213-2600(14)70169-9

中图分类号：

R4 [临床医学];

学科分类号：

100218 [急诊医学];

摘要：

Inhaled corticosteroids are widely used in chronic obstructive pulmonary disease (COPD) and, in combination with long-acting beta(2) agonists, reduce exacerbations and improve lung function and quality of life. However, inhaled corticosteroids have been linked with an increased risk of pneumonia in individuals with COPD, but the magnitude of this risk, the effects of different preparations and doses, and the mechanisms of this effect remain unclear. Therefore, making informed clinical decisions balancing the beneficial and adverse effects of inhaled corticosteroids in individuals with COPD-is difficult. Understanding of the mechanisms of increased pneumonia risk with inhaled corticosteroids is urgently needed to clarify their role in the management of COPD and to aid the development of new, safer therapies.

引用

收藏

页码：919 / 932

页数：14

相关论文

共 127 条

[1]

Inhaled drugs as risk factors for community-acquired pneumonia [J].

Almirall, J. ;

Bolibar, I. ;

Serra-Prat, M. ;

Palomera, E. ;

Roig, J. ;

Hospital, I. ;

Carandell, E. ;

Agusti, M. ;

Ayuso, P. ;

Estela, A. ;

Torres, A. .

EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (05) :1080-1087

[2]

Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia [J].

Almirall, Jordi ;

Bolibar, Ignasi ;

Serra-Prat, Mateu ;

Palomera, Elisabet ;

Roig, Jordi ;

Hospital, Imma ;

Carandell, Eugenia ;

Agusti, Merce ;

Ayuso, Pilar ;

Estela, Andreu ;

Torres, Antoni .

PLOS ONE, 2013, 8 (09)

[3]

Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes [J].

Anzueto, Antonio ;

Ferguson, Gary T. ;

Feldman, Greg ;

Chinsky, Kenneth ;

Seibert, Allan ;

Emmett, Amanda ;

Knobil, Katharine ;

O'Dell, Dianne ;

Kalberg, Christopher ;

Crater, Glenn .

COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2009, 6 (05) :320-329

[4]

Synergistic Effects of p38 Mitogen-Activated Protein Kinase Inhibition with a Corticosteroid in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease [J].

Armstrong, J. ;

Harbron, C. ;

Lea, S. ;

Booth, G. ;

Cadden, P. ;

Wreggett, K. A. ;

Singh, D. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (03) :732-740

[5]

Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages [J].

Armstrong, J. ;

Sargent, C. ;

Singh, D. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 158 (01) :74-83

[6]

Fluticasone propionate reduces bacterial airway epithelial invasion [J].

Barbier, M. ;

Agusti, A. ;

Alberti, S. .

EUROPEAN RESPIRATORY JOURNAL, 2008, 32 (05) :1283-1288

[7]

Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations [J].

Berenson, Charles S. ;

Kruzel, Ragina L. ;

Eberhardt, Ellana ;

Dolnick, Ree ;

Minderman, Hans ;

Wallace, Paul K. ;

Sethi, Sanjay .

THORAX, 2014, 69 (09) :811-818

[8]

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].

Burge, PS ;

Calverley, PMA ;

Jones, PW ;

Spencer, S ;

Anderson, JA ;

Maslen, TK .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303

[9]

Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? [J].

Burgel, Pierre-Regis ;

Deslee, Gaetan ;

Jebrak, Gilles ;

Brinchault, Graziella ;

Caillaud, Denis ;

Chanez, Pascal ;

Court-Fortune, Isabelle ;

Escamilla, Roger ;

Nesme-Meyer, Pascale ;

Paillasseur, Jean-Louis ;

Perez, Thierry ;

Roche, Nicolas .

EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (04) :1201-1203

[10]

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].

Calverley, Peter M. A. ;

Anderson, Julie A. ;

Celli, Bartolome ;

Ferguson, Gary T. ;

Jenkins, Christine ;

Jones, Paul W. ;

Yates, Julie C. ;

Vestbo, Jorgen ;

Calverley, P. M. A. ;

Anderson, J. A. ;

Celli, B. ;

Ferguson, G. T. ;

Jenkins, C. ;

Jones, P. W. ;

Knobil, K. ;

Yates, J. C. ;

Vestbo, J. ;

Cherniack, R. ;

Similowski, T. ;

Cleland, J. ;

Whitehead, A. ;

Wise, R. ;

McGarvey, L. ;

John, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789

← 1 2 3 4 5 6 7 8 9 10 →